Investor Newsletter

Issue 06 2016

MicroPort

MPSC 2016 Annual General Meeting Held

MicroPort Scientific Corporation (HK:853) ("MPSC") 2016 Annual General Meeting ("AGM") was held on June 27 in its Shanghai headquarters. Board of Directors including Executive Director Dr. Zhaohua Chang, Non-executive Directors Hiroshi Shirafuji and Norihiro Ashida, Independent Non-executive Directors Dr. Guoen Liu and Jonathan H. Chou, attended the meeting.

During the meeting, MPSC Chief Finance Officer Martin Sun, MPSC Chief Marketing Officer Bo Peng, MPSC Chief Technology Officer Dr. Qiyi Luo, President of MicroPort Orthopedics Aurelio Sahagun and Jonathan Chen, MPSC Senior Vice President of International Operations and Investor Relations, answered questions raised by shareholders.

According to Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited, all the proposed resolutions as set out in the notice of the AGM dated 13 May 2016 were taken by poll, and the poll results were published on the official website of Shanghai MicroPort Medical (Group) Co (www.microport.com) and the website of The Stock Exchange of Hong Kong Ltd (www.hkexnews.hk).

MicroPort® Attends SOLACI 2016

Shanghai MicroPort Medical (Group) Co ("MicroPort®") recently attended the Society of Latin American Cardiology Intervention 2016 ("SOLACI 2016") with about 2,000 experts from South America in attendance. MicroPort® hosted a dinner party to celebrate the market launch of Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk®") in Brazil, and rebroadcasted a surgery using Firebird2® Rapamycin-Eluting Coronary CoCr Stent ("Firebird2®"). SOLACI 2016 provided a platform for South American experts and distributors to gain deeper understanding in MicroPort®'s innovative products and its capabilities of sustained innovation, paving the way for MicroPort® to further expand the South American market to serve more overseas patients.



MicroPort

Firehawk® Approved for Market Launch in Brazil

Firehawk® was approved for market launch by the National Health Surveillance Agency (in Portuguese, Agência Nacional de Vigilância Sanitária - ANVISA), a regulatory body of the Brazilian government, on June 13. This is the second market approval Firehawk® gains in South America, following that in Peru, allowing the device to benefit more patients in the region.

MicroPort



MicroPort® Attends OCC 2016

MicroPort® recently attended the 10th Oriental Congress of Cardiology ("OCC 2016") in Shanghai Expo Center, to further prove the safety and efficacy of Firehawk® by sharing results and cases of its TARGET Serial Clinical Trials. Meanwhile, MicroPort® displayed its innovative products of various business segments including cardiovascular, electrophysiological and pacemaker devices. In particular, it was the first time for products like Columbus® 3D EP Navigation System ("Columbus®") to appear in OCC, which attracted the attention from many professionals.

MicroPort

Firesorb™ Granted Green Channel Status for CFDA Approval

Firesorb™ Bioresorbable Rapamycin Target Eluting Coronary Scaffold System ("Firesorb™"), the second-generation fully bioresorbable scaffold in-house developed by MicroPort®, was recently granted by China Food and Drug Administration ("CFDA") the Green Channel status, a special fast-track procedure for innovative medical devices to gain CFDA approval. This will significantly shorten the approval time, and MicroPort® is expected to provide a better solution of bioresorbable scaffold to domestic patients with coronary heart diseases in the near future.

Firehawk® Gains CFDA Approval to Extend Shelf Life to Two Years

MicroPort® recently gained approval from CFDA to extend the shelf life of its in-house developed Firehawk® to two years. Firehawk® was approved for market launch by the CFDA in 2014, and was approved to add 24 specifications in 2015.



MicroPort

PROFEMUR™ TL
Classic Stem Receives Approval from MHLW

MicroPort® Orthopedics Japan received an approval for PROFEMUR™ TL Classic Stem from Ministry of Health, Labour and Welfare ("MHLW") in the end of May.



厚生労働省
Ministry of Health, Labour and Welfare

MicroPort

MicroPort® OrthoRecon Attends the Fourth Academic Meeting of CKS

From June 17 to June 19, Suzhou MicroPort OrthoRecon ("MicroPort® OrthoRecon") attended the Fourth Academic Meeting of Chinese Knee Society ("CKS") which was hosted by Chinese Medical Association and Joint Surgery Branch of Chinese Orthopaedic Association in Hefei, Anhui Province. During the congress, MicroPort® OrthoRecon held a satellite meeting, which attracted around 500 domestic surgeons. Professor Zhihong Liu, from Ruijin Hospital of Shanghai Jiao Tong University School of Medicine, introduced in detail the design concept of EVOLUTION™ Medial-Pivot Knee System ("EVOLUTION™") to attendees. He pointed out that EVOLUTION™ was designed based on the excellent clinical history of ADVANCE® Medial-Pivot Total Knee, which was launched in 1998. In 2010, EVOLUTION™, the second-generation of MicroPort® Medial-Pivot total knee implant, was launched.
All Medial-Pivot total knee implants feature ball-in-socket articulation which enhances stability and allows the prosthesis to move and feel more like a normal knee.

MicroPort® OrthoRecon Attends CAOS 2016

MicroPort® OrthoRecon recently attended the 9th Congress of Chinese Association of Orthopaedic Surgeons ("CAOS 2016") that was held in Chengdu, Sichuan. As an influential congress in the orthopedic field, CAOS 2016 attracted around 9,000 orthopedic surgeons, and meanwhile it was watched live on the Internet by over 100,000 people.

In the Hip Session of the congress, Professor Pei Yang of the Second Affiliated Hospital of Xi'an Jiaotong University shared SuperPath™ Micro-posterior Total Hip Arthroplasty Surgical Technique ("SuperPath™") with surgeons in attendance. He explained the key surgical techniques of SuperPath™ with lots of anatomical illustrations, and noted that SuperPath™ will facilitate surgeons to achieve better post-operative outcome.

MicroPort



First Use of EVOLUTION™ in Macao

Macao's first surgery using EVOLUTION™ was successfully completed in a local hospital Centro Hospitalar Conde de São Januário ("CHCSJ"). This case represents a milestone in EVOLUTION™'s market expansion. With the growing demand for knee replacement, it is expected that this second-generation medial-pivot knee system will gain higher recognition among patients and surgeons.





FireMagic® Obtains CFDA Registration Certificate

MicroPort® EP recently obtained the registration certificate of CFDA for its in-house developed FireMagic® Irrigated Ablation Catheter ("FireMagic®"). FireMagic®, combined with Columbus®, is mainly used in the treatment for drug resistant atrial fibrillation. Columbus® was granted the CFDA approval earlier this year. With both of them officially launched, MicroPort® EP provides physicians with a comprehensive solution for the diagnosis and treatment of complex arrhythmias.

MicroPort

MicroPort® EP Attends CARDIOSTIM-EHRA EUROPACE 2016



Shanghai MicroPort EP MedTech Co ("MicroPort® EP") recently attended the 20th CARDIOSTIM-EHRA EUROPACE ("CARDIOSTIM-EHRA EUROPACE 2016") and displayed its in-house developed Columbus®.

CARDIOSTIM2016
EHRA EUROPACE
June 8-11
Nice - France

MicroPort

Dongguan Kewei's Polypropylene Hernia Mesh Granted CFDA Approval

Dongguan Kewei Medical Instrument Co ("Dongguan Kewei"), a wholly-owned subsidiary of MicroPort®, obtained a registration certificate from CFDA for its in-house developed Polypropylene Hernia Mesh (product name: THUNDERBIRD®• PURETM) on June 24.

The Polypropylene Hernia Mesh is a sheeted product or three-dimensional combination product made of polypropylene monofilaments by specific weaving technique, mainly used in open tension-free herniorrhaphy or laparo-scopic herniorrhaphy, to replace weakened tissues or fill the defect area. Fixed with certain surgical procedures, the product can bear tension and pressure from the abdomen, and effectively prevent organ prolapse. Its mesh structure provides scaffold for human cells to grow and climb, so as to achieve repair effect. The Polypropylene Hernia Mesh that gains the CFDA approval this time offers six forms and 49 specifications.

MicroPort

Investor Newsletter

Issue 06 2016

MicroPort

For more information, please contact:

Martin Sun
Chief Financial Officer
Shanghai MicroPort Medical (Group) Co., Ltd. (HQ)
Tel: (86)(21) 38954600
Email: ir@microport.com

Leanne Li
Board Secretary & Senior Director of External Affairs
Shanghai MicroPort Medical (Group) Co., Ltd. (HQ)
Tel: (86)(21) 38954600
Email: ir@microport.com